Trial Search Results

A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Andrei Iagaru

Collaborator: General Electric

Intervention(s):

  • Drug: 68Ga RM2
  • Drug: 68Ga-PSMA-11
  • Device: Investigational PET scanner coils and software

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Suspected prostate cancer

   - Planned prostate biopsy

   - Able to provide written consent

   - Karnofsky performance status of 50 (or ECOG/WHO equivalent)

Exclusion Criteria:

   - Patients not capable of getting PET study due to weight, claustrophobia, or inability
   to lay still for the duration of the exam

   - Metallic implants (contraindicated for MRI)

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jordan Cisneros
650-725-6409
Recruiting